In other words: this isnt a peak, its a new baseline
One clinical trial gives a clearer picture of how often these side effects showed up at higher doses: Dysesthesia refers to unusual or unpleasant skin sensationsthings like tingling, burning, prickling, or a feeling that skin is overly sensitive to touch, sometimes described as a sunburned feeling without any visible cause
They are part of the reason large Phase 3 programmes and regulatory reviews are needed
GLP-3 RETA, also known as LY3437943 , is a synthetic research peptide that functions as a triple receptor agonist targeting the GLP-1, GIP, and glucagon receptors
FIGURE 4 4 Comparative overview of mainstream GLP-1RAs Over the past 2 decades, several GLP-1RAs have entered clinical practice, including short-acting exenatide, intermediate-acting liraglutide, and long-acting formulations such as dulaglutide and semaglutide, as well as the newer dual agonist tirzepatide